Immunome (NASDAQ:IMNM) Receives New Coverage from Analysts at JPMorgan Chase & Co.

Stock analysts at JPMorgan Chase & Co. began coverage on shares of Immunome (NASDAQ:IMNM) in a note issued to investors on Tuesday, Marketbeat reports. The firm set an “overweight” rating and a $24.00 price target on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 63.38% from the company’s current price.

Several other analysts have also recently issued reports on the company. SVB Leerink initiated coverage on Immunome in a research report on Monday, January 29th. They set an “outperform” rating and a $30.00 target price for the company. Leerink Partnrs restated an “outperform” rating on shares of Immunome in a report on Monday, January 29th. Guggenheim started coverage on Immunome in a report on Monday, April 15th. They set a “buy” rating and a $35.00 price target for the company. Finally, Wedbush raised their price target on Immunome from $27.00 to $33.00 and gave the company an “outperform” rating in a report on Monday, April 1st. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $30.50.

Immunome Trading Up 4.5 %

NASDAQ:IMNM opened at $14.69 on Tuesday. Immunome has a 12-month low of $4.50 and a 12-month high of $30.96. The stock has a 50-day moving average price of $21.58 and a 200 day moving average price of $15.28. The stock has a market capitalization of $880.52 million, a P/E ratio of -2.73 and a beta of 1.66.

Immunome (NASDAQ:IMNM) last released its earnings results on Thursday, March 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.26). Immunome had a negative return on equity of 69.74% and a negative net margin of 761.92%. The business had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $3.40 million. On average, research analysts predict that Immunome will post -1.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunome

Institutional investors have recently modified their holdings of the stock. Dorsey Wright & Associates bought a new stake in shares of Immunome in the 3rd quarter valued at approximately $26,000. Jump Financial LLC bought a new stake in shares of Immunome in the 4th quarter valued at approximately $172,000. Clear Creek Financial Management LLC bought a new stake in shares of Immunome in the 1st quarter valued at approximately $547,000. Capstone Investment Advisors LLC bought a new stake in shares of Immunome in the 1st quarter valued at approximately $1,044,000. Finally, Acadian Asset Management LLC bought a new stake in shares of Immunome in the 3rd quarter valued at approximately $414,000. 44.58% of the stock is owned by institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.